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CObjectives: For rare diseases it may be difficult to generate data from
randomized trials to support fundingof adrug. Enzymereplacement ther-
apies for diseases of inherited metabolic enzyme deficiency provide an
exampleof thisdilemma.TheOntarioPublicDrugProgramsconvened the
Drugs for Rare Diseases Working Group to develop a policy for assessing
these drugs. Methods: The Drugs for Rare Diseases Working Group de-
veloped terms of reference expecting that the ideal policy product would
be transparent and consistent and address unique aspects of the treat-
ment of a specific rare conditionwhile being adaptable to other dissimilar
conditions. The perspective was that of a public payer addressing re-
quests for funding generated for a specific drug, and included respect for
theprinciples of “accountability for reasonableness” ofDaniels andSabin.
Results: A seven-step frameworkwas developed and tested by using the O
Cen
al So
http://dx.doi.org/10.1016/j.jval.2012.06.009ase study of idursulfase for mucopolysaccharidosis II (Hunter disease).
stimation of clinical effectivenesswas done by using decisionmodeling.
he model developed informed funding recommendations and ulti-
ately led to an agreement with the manufacturer allowing funding of
dursulfase in Ontario. Conclusions: This policy framework attempts to
ddress the policy challenges of funding drugs for rare diseases. The
rameworkwill be used to assess other drugs in future andwill inevitably
equiremodificationwith experience. It is hoped that itmaybe of value to
ther policymakers.
eywords: cost-effectiveness, drug reimbursement, health policy, gly-
ogen storage disease, mucopolysaccharidosis.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In this article, we describe the development of a unique, evidence-
based framework for the evaluation of drugs intended for the
treatment of rare diseases. This framework was developed at the
request and with the support of the Ontario Public Drug Programs
of the Ministry of Health and Long-term Care in the province of
Ontario, Canada. The purpose of the evaluation framework is to
provide guidance for public drug-funding policy from the payer
perspective. The framework consists of seven evaluative steps,
each prerequisite for those that follow, and include steps of mod-
eling of both effectiveness and cost-effectiveness. The evaluation
framework was tested by using the case study of idursulfase for
Hunter disease, and this is provided by way of example.
Background
Over the past decade, expensive enzyme replacement therapies
for rare inherited metabolic enzyme deficiencies have emerged.
These drugs are among the most expensive in the world (Table 1)
and have created dilemmas for public drug payers [1–3]. Typically,
* Address correspondence to: Eric Winquist, London Health Sciences
E-mail: eric.winquist@lhsc.on.ca.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.data from adequately powered randomized clinical trials are re-
quired for both regulatory approval and public funding of most
new drugs in Canada, which is decided at the provincial level.
Escalating health care costs have led to greater provincial scrutiny
of drug expenditures and increasing consideration of the cost of a
drug to inform drug-funding decisions [4]. An approach consider-
ing health gain, incremental cost-effectiveness, and global budget
impact has been adopted in Ontario.
To assess cost-effectiveness adequately as a part of such a pro-
cess requires adequate information about the effectiveness of a
new drug from randomized trials, and for rare conditions, such
information is often limited, inadequate, or absent. There is little
guidance available in the published literature or from other juris-
dictions to guide the evaluation of drugs for funding in such situ-
ations [5]. The Canadian provinces and territories have attempted
to develop a national strategy, but in the absence of a funding
commitment from the federal government, thiswork has stopped,
and so provincial funding recommendations considering efficacy
and value for money in a conventional manner are typically neg-
ative [6].
The Ontario Public Drug Programs was formally established in
April 2007, led by an ExecutiveOfficerwho is investedwith author-
tre, 790 Commissioners Road East, London, ON, Canada N6A 4L6.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
(all p
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including themandate to administer Ontario’s $4.1 billion publicly
funded drug programs [7]. The Committee to Evaluate Drugs (CED)
makes recommendations for drug funding to the Executive Officer
on the basis of clinical, safety, and cost-effectiveness data. Con-
sistent with recommendations from the Canadian Drug Expert
Committee, the CED had recommended against funding idursul-
fase for Hunter disease because it did not satisfy the usual criteria
for clinical benefit and cost-effectiveness [6]. However, adherence
to such criteria could appear unfair to patients stricken with a
disabling and sometimes fatal condition, and who are often in-
fants or children [8]. In view of the varied approaches taken in
other Canadian provinces to the funding of idursulfase for Hunter
disease and in an effort to address public demands fairly, the Ex-
ecutive Officer prioritized the development of a process for re-
viewing such drugs for funding in a fair, transparent, and consis-
tent way.
A “Drugs for Rare Diseases Working Group” was created con-
sisting of nine members selected by the Executive Officer: three
representatives from the Ontario Ministry of Health and Long-
term Care (the Executive Officer and two pharmacists), four mem-
bers of the CED (two physicians, a pharmacist, and a health
economist), and two other individuals, one with formal phar-
macoeconomic training and an expert in the treatment of inher-
ited disorders of metabolism in children. An ethicist was con-
sulted ad hoc during the process.
Development of the Framework
The Drugs for Rare Diseases Working Group had broad latitude to
develop its own terms of reference and process. Several principles
formed the basis of the development process. First, there was an
expectation that the resulting policy product would be transpar-
ent and consistent and address the unique aspects of treatment of
a specific rare condition while being adaptable to other rare but
dissimilar conditions in future. Second, it was recognized that the
framework should respect and be complementary with the cur-
rent policies of the Ontario Public Drug Programs and the Ministry
and that the perspective would be that of a public payer address-
ing requests for funding generated for a specific candidate drug
rather than general treatment algorithms for a specific condition.
Finally, as the overall aim was to develop a funding framework
that considered the evidence available, patient need, and the cur-
rent funding gap, it was specified that the conditions for “account-
ability for reasonableness” of Daniels and Sabin [9] for fair priority-
setting be respected. These provide ethical guidance for making
difficult decisions under constrained resources and include four
domains: Publicity (decisions to limit health care and their ratio-
nales must be publicly accessible), Relevance (the rationales in-
voked must be based on evidence, reasons, and principles that
fair-minded persons would affirm), Appeals (mechanisms for
Table 1 – The most expensive drugs in the world [1].
Drug Indication
Soliris (eculizumab) Paroxysmal nocturnal hemoglo
Elaprase (idursulfase) Hunter’s syndrome
Naglazyme (galsulfase) Maroteaux-Lamy syndrome
Cinryze (C1 esterase inhibitor) Hereditary angioedema
Myozyme (alglucosidase alpha) Pompe disease
Arcalyst (rilonacept) Cryopyrin-associated periodic s
Fabrazyme (agalsidase beta) Fabry disease
Cerezyme (imiglucerase) Gaucher disease
Aldurazyme (laronidase) Hurler syndrome
Note. From 2010 data provided by Forbes and Pharmaceutical Commercechallenging allocation decisions must exist), and Regulation (pub-lic procedures must ensure the fulfillment of these three condi-
tions). Appeal of drug-funding decisions in Ontario is available
through the office of the Executive Officer.
Policy Framework
No acceptable processes developed by other jurisdictions were
identified for adoption, and so a seven-step framework was devel-
oped that addressed specific areas of uncertainty related to drugs
for rare diseases that emerged early inWorking Group discussions
(Fig. 1). These included the following: Is the condition truly rare?
Is it logical that patients could benefit from the treatment?What is
the potential value of the treatment and to whom? It was also
recognized that expert input was crucial and that the framework
should be responsive to accumulating knowledge about the
disease.
Step 1: Confirm the condition for treatment with the candidate
drug is truly “rare”
In the context of this framework, it was considered of critical im-
portance to define what constituted “rare.” It was agreed that the
existence of such a policy process should not diminish the moti-
vation to conduct randomized trials in conditions that were sim-
ply uncommon or difficult to study. Rare health conditions have
been defined as liberally as a population prevalence of 1/1500 [10].
As well, with improved case finding and international collabora-
Annual cost Company
ia $409,500 Alexion
$375,000 Shire
$365,000 BioMarin
$350,000 ViroPharma
$300,000 Genzyme
omes $250,000 Regeneron
$200,000 Genzyme
$200,000 Genzyme
$200,000 Genzyme, BioMarin Pharmaceutical
rices in US dollars).
Fig. 1 – Policy framework for funding drugs for rarebinur
yndrdiseases.
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984 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 8 2 – 9 8 6tion, diseases once considered rare by clinicians, public payers, or
the pharmaceutical industry may be quite feasibly evaluated in
randomized trials. As an example, gastrointestinal stromal tu-
mors were once considered to be a rare disease but have now been
well studied in large randomized trials [11,12].
It was the consensus that for the purpose of consideration for
xceptional funding, a “rare disease” should be one for which ran-
omized trials would be impossible to complete within a reason-
ble period of time, based on current knowledge of its frequency
nd/or the place of the drug in therapy. Ideally, the definition
hould be disease and outcome specific and extrapolated from
n estimate of the sample size required to complete a random-
zed trial studying the intervention in question, but this defini-
ion requires further methodological development. For the pur-
ose of developing the initial framework, a more stringent
efinition of an annual incidence of 1:150,000 live births in Can-
da was agreed to as an upper threshold. It was also agreed that
xceptions could be considered on the basis of mitigating fac-
ors such as the vulnerability of the population (e.g., early in
ife), severity of the disease, and potential impact of treatment
n health outcomes (e.g., curative vs. palliative). A disease or
ondition not meeting these criteria would be removed from
urther consideration at this step.
Step 2: Understand the disease
This step invests time understanding the basic pathophysiology,
natural history, and health effects of the condition under consid-
eration. Such knowledge was considered essential to critically re-
view and fully understand the mechanism of action of the candi-
date drug and its actual or potential effects on the natural history
and health of the patients. As these diseases are by definition rare,
this step requires engagement, participation, and collaboration
with experts in the disease as well as supplemental information
from the medical literature and other sources to address both the
disease and the treatment.
Step 3: Understand the potential value of the candidate drug
This step evaluates the theoretical value of the drug. Randomized
Table 2 – Bradford Hill [15] criteria for causality modified fo
Criterion
Strength Disease improvements strongly associated w
Hunter’s syndrome is inexorably progressive,
have been observed with idursulfase therap
Consistency Disease improvements have been repeatedly
stage, and therapy:
There are several reports of disease improvem
different disease burden treated with varyin
Specificity Benefit with the drug is specific to the disease
Idursulfase has not been tested in other disea
Temporality Disease improvements occur after drug expo
Benefits of idursulfase occur after prolonged d
Biological gradient Optimal disease improvements are associated
Idursulfase 0.5 mg/kg infused weekly was ass
associated with more benefit than placebo
Plausibility Drug mechanism addresses underlying disea
Idursulfase therapy replaces the enzyme defic
Coherence Observations of drug effects do not conflict w
Idursulfase therapy is most effective for reduc
neurological involvement.
Experiment Experimental data confirm disease improvem
A single placebo-controlled randomized trial r
of 6-minute walk and percentage forced vit
Analogy Drugs of similar mechanism improve similar
Enzyme replacement therapy has been associ
deficiency, e.g., Gaucher’s disease.controlled trials are generally considered the gold standard of ev-idence when evaluating the efficacy of a new drug technology. If
randomized trials reporting clinically relevant outcomes were
available and considered adequate to assess clinical effectiveness,
then review using this framework would not be necessary; how-
ever, if not, then the use of this framework would be appropriate.
All relevant and accessible clinical data are considered. Surrogate
end points should be scrutinized for validity at this step [13,14].
Where clinical data are sparse or questionable, the criteria de-
scribed by Bradford Hill [15] for assessing causation between an
exposure and a disease were adapted for use as a guide and to
screen interventions at this step. Adaptation of these to therapy
requires one to consider the candidate drug the “exposure” and
the beneficial effects of this treatment as the “disease” (Table 2).
Bradford Hill did not intend either that his criteria provide proof of
causality or be used as a checklist. In this case, the purpose of
using these criteria is to assist in answering the fundamental
question: Is there any other way of explaining the effects seen in
patients treated other than the drug? A candidate drug not con-
sidered potentially “causal” of tangible patient benefits should be
removed from further consideration at this step.
Step 4: Model the potential clinical effectiveness of the
candidate drug
From the data identified in step 3, clinical effectiveness can be
estimated bymodeling by using clearly describedmethods includ-
ing estimates of the variability of treatment effects and acknowl-
edgment of the limitations of the data and techniques used. Deci-
sionmodeling adopting a Bayesian perspective has some appeal in
this setting as it allows the synthesis of data of different degrees of
quality emanating from alternative sources. Other techniques to
estimate a candidate drug’s treatment effect, however, may be
quite reasonable and appropriate.
Step 5: Evaluate cost implications and generate a funding
recommendation
Once estimates of clinical effectiveness are available, cost-effec-
tiveness can be theoretically calculated by using conventional
atment assessment.
Example
ug exposure:
pontaneous improvements are not seen. Disease improvements
iated with drug exposure despite variations in population, disease
ith idursufase therapy by different investigators in patients with
ses and schedules of therapy.
isease mechanism:
xposure.
optimal drug doses:
d with more benefit than alternate weekly infusions, which were
andomized trial.
thophysiology:
in Hunter’s syndrome.
nerally known facts of natural history and biology of the disease:
of hepatosplenomegaly and appears ineffective in patients with
ith drug exposure:
ted a statistically significant improvement in a composite end point
acity at 1 y.
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with clinical benefits in other inherited disorders of enzymer tre
ith dr
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atedtechniques, such as cost minimization, or incremental costs per
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generally considers drugs to be cost-effective if the cost per qual-
ity-adjusted life-year gained is in the range of $40,000 to $60,000 or
less, a threshold acknowledged as unlikely to be useful or achiev-
able for most expensive drugs developed for the treatment of rare
diseases. Estimation of budget impact, however, may be of partic-
ular importance at this step. The cost data generated can also be
used to inform individual or group funding decisions, more pre-
cisely define the “funded” population, develop a budget for a rare
disease portfolio, and identify areas for risk sharing to support
price negotiations.
Step 6: Review the drug evaluation with disease experts and
stakeholders
As the proposed process is unique, complex, and variable with the
disease and drug under consideration, it is considered essential
that independent disease experts not involved in the Working
Group review the inputs, assumptions, and outputs to detect areas
of significant disagreement or error. This helps to ensure validity
of any modeling used. It is also essential that experts and other
stakeholders including the public understand the process to facil-
itate acceptance of its conclusions.
Step 7: Reassessment
It is important to continuously review and incorporate new infor-
mation regarding disease incidence, natural history, and the effec-
tiveness or cost of candidate drug therapy. Potential impact on
modeled effectiveness and/or cost-effectiveness estimates should
trigger reanalysis with incorporation of the new data.
Test of the Framework
The evaluation framework was tested by evaluating idursulfase
for mucopolysaccharidosis II (Hunter disease). Hunter disease has
an estimated incidence of 1 in 170,000male live births (1 to 2 births
per year in Ontario), meeting criteria for a rare disease for public-
funding purposes in Ontario [16] (step 1). It is an X-linked disorder
caused by a deficiency of the lysosomal enzyme iduronate-2-sul-
fatase resulting in the accumulation of glycosaminoglycans in tis-
sues and organs, causing the signs and symptoms of the disease
[16]. Multiple organs are affected, and both age of onset and rate of
progression are variable. Traditionally, Hunter disease patients
have been categorized into two types: patients with type A, who
have severe primary neurological involvement, which inevitably
culminates in death by the end of the second decade of life, and
patients with type B, who do not have primary neurological in-
volvement and have reduced life expectancy because of the in-
creased risk of respiratory, cardiac, and cardiorespiratory compli-
cations of the disease (step 2).
Idursulfase therapy replaces iduronate-2-sulfatase and satis-
fies eight of the nine modified Bradford Hill criteria (Table 2), con-
firming the potential of benefit to patients with Hunter disease.
Clinical data have not shown benefit of idursulfase in patients
with type A Hunter disease, supporting an approach focused on
identifying and treating patients with type B Hunter disease (step
3). One available randomized trial had been reviewed by the CED
andwas considered inadequate to assess clinical effectiveness [6].
Review of the natural history of Hunter disease and effects of
treatment with idursulfase led to agreement with this recommen-
dation against routine use as palliative therapy in patients with
advancedmultisystemdisease. Idursulfasewas considered poten-
tially able to arrest or preventmultisystemmorbidity and possibly
even prolong life if initiated when disease effects were minimal
early in childhood. It was also acknowledged that patients des-
tined to develop severe neurological involvement would be un-
likely to benefit significantly from therapy. A Markov modeling
approachwas developed to generate amodel of the natural historyof the disease incorporating estimates of small, moderate, and
large effects of idursulfase therapy (Fig. 2) [17]. This demonstrated
that idursulfase might lead to prolonged life expectancy for pa-
tients with type B Hunter disease (step 4). For example, if idursul-
fase treatment reduced disease progression by 10%, 20%, and 50%,
life expectancy gains of 1.32, 2.93, and 10.66 years, respectively,
were observed for a 12-year-old patientwith type BHunter disease
with only musculoskeletal symptoms. However, the same treat-
ment resulted in life expectancy gains of only 0.03, 0.06, and 0.16
years, respectively, for an 11-year-old patient with type A Hunter
disease with severe neurocognitive and respiratory problems.
The per-patient cost of idursulfase is in the range of $375,000
per year. Detailed cost analysiswas not done because the drugwas
not considered cost-effective by conventional criteria even in the
most extrememodel scenarios. However, the potential life expec-
tancy gains in type B patients were considered highly valued. This
was reviewed and approved by the Executive Officer, and a fund-
ing algorithm was developed for negotiation with the manufac-
turer (step 5). A review of the Markov model by content expert
physicians was conducted. This led to revision of some assump-
tions and general approval of the process and its results. The
framework was also presented to and approved by the Ontario
Public Drug Programs Citizens’ Council (step 6). Negotiations with
the manufacturer led to the public funding of idursulfase in On-
tario for patients 6 years or older without neurocognitive symp-
toms, while the manufacturer manages requests for funding for
patients younger than 6 years of age in whom the potential
effects on life expectancy were far less certain [18]. This has
provided an estimate of the annual cost of idursulfase to On-
tario Public Drug Programs prioritized to those patients most
likely to benefit. No new information informing the model has
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Fig. 2 – Schematic representation of Markov model for
main health states in Hunter disease. (A) Progression of
Hunter disease symptoms. (B) Progression of neurological
deficit in Hunter disease.been identified to date (step 7).
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Our evaluation framework has a number of limitations. It assumes
the availability of adequate information about disease incidence
and natural history. This may not always be the case. For the case
study used to test the framework, a Bayesian approach using
Markov modeling was employed to estimate ranges of clinical ef-
fectiveness on the basis of outcomes and clinical scenarios not
studied in clinical trials. Critics of such an approachmight suggest
that such estimates are highly speculative and prone to error.
However, we feel that this approach is defensible, because it is
based on the most contemporary data and expert opinion avail-
able relevant to the disease, utilizes reasonable expectations of
effectiveness at a point in the disease processwhen these aremost
likely to be realized, and can be adapted and updated to include
new data about the disease and drug as this information becomes
available.
The dilemma of funding drugs for rare disease is not unique to
Ontario, and a number of strategies have been proposed [19]. The
US Orphan Drug Act provides incentives for pharmaceutical com-
panies to develop drugs; however, individual patients are left to
rely on public or private reimbursement programs that are likely
not to fund the drugs because of limited evidence and high cost. It
has been argued that a more utilitarian approach should be used
when it comes to orphan drugs and that rarity of a disease is a
limited justification. For example, in the United Kingdom, the pri-
mary care trusts of West Midlands commissioned a report on the
ethical issues, clinical efficacy, cost-effectiveness, and public per-
spective on whether to reimburse patients with Fabry disease and
other rare diseases for the costs of treatment [20]. It was agreed
that rarity was not significant enough a factor to override all other
considerations in developing a decision. As a principled argument
could not be made to distinguish patients with rare diseases from
those with common diseases who also had unmet treatment
needs, along with poor cost-effectiveness, the trust denied reim-
bursement of treatments for Fabry disease and also discontinued
reimbursement of treatment for new cases of Gaucher disease. A
balance betweenpureutilitarianismbasedon cost-effectiveness and
patient nonabandonment must be struck, but how this should be
done in an evidence-based public health context is uncertain [19].
Conclusions
Our evaluation framework attempts to systematically address the
many challenges raised when considering funding new drugs for
rare diseases—many ofwhich are expensive—within an evidence-
based publicly funded drug program. If it is accepted that it is truly
impractical to perform adequately powered randomized clinical
trials, thenwe believe that funding decisionsmust be addressed in
a consistent, fair, and transparent manner. In the case study we
have described, modeling of effectiveness supported potential
benefits including prolonged life expectancy in a subgroup of pa-
tients. This advice led to a unique funding algorithm for this drug
in Ontario. This framework is an iterative process that inevitably
will require modification with experience. Feedback will be ob-
tained through a series of meetings with patient, physician, and
stakeholder groups, the pharmaceutical industry, and other inter-
ested parties. This evaluation framework attempts to identify an
evidence-derived “middle ground” that is an improvement over
arbitrary decisions based on either the absence of specific data orpolitical expediency. It is hoped that it can be of value for the
assessment of other drugs in future; however, it cannot be consid-
ered a cipher for uncritical assignment of drug therapy.
Source of financial Support: The development of this frame-
work was supported by public funding from the Ontario Public
Drug Programs of theMinistry of Health and Long-termCare of the
Province of Ontario, Canada.
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